Skip to content

Company research · Pfizer

Pfizer: $15.0B Q2 2026 Revenue

The question

What is Pfizer: what does it do, how big is it and how is it doing, who owns and funds it, who runs it, and how do the company and the press describe it?

The 14 searches GAR ran
  • site:pfizer.com investor relations annual report 2025
  • site:pfizer.com newsroom press release
  • Pfizer news 2026
  • Pfizer criticism controversy concerns
  • Pfizer company what it does products services
  • Pfizer company overview founded headquarters industry
  • Pfizer annual revenue employees 2025
  • Pfizer revenue profit results 2026
  • Pfizer funding round raised investors valuation
  • Pfizer owner parent company stock listing
  • Pfizer CEO founder leadership team
  • Pfizer chief executive executives board
  • Pfizer press release announcement 2026
  • Pfizer mission strategy statement

GAR’s answer

Pficer is a New York-based pharmaceutical company that reported $15.0B in revenue for the quarter ending June 28, 2026.

What we found

What it does

Pfizer Inc. is a New York-based pharmaceutical company that serves healthcare systems, clinicians, patients, and other stakeholders. The company provides prescription medicines, vaccines, and related scientific capabilities. Its business model relies on discovering, developing, manufacturing, and supplying regulated therapies at scale. Pfizer operates through payer, government, provider, and distribution channels across international markets. The company is known for products including Advil, Viagra, Xanax, and Zoloft. Pfizer was founded in 1849 and maintains its headquarters in New York. [5] [6] [7]

The numbers

Pfizer reported annual revenue of $62.6B for the twelve months ending December 31, 2025, according to data from wallstreetzen.com. This figure aligns with the revenue of 62579000000 USD reported in the company's annual SEC filing for the period ending December 31, 2025. In the preceding year, for the period ending December 31, 2024, the company reported revenue of 63627000000 USD in its SEC filing. The year-over-year revenue growth for the twelve months ending December 31, 2025, was -1.6%. For the second quarter of 2026, ending June 28, 2026, Pfizer recorded quarterly revenue of $15.0B. The year-over-year revenue growth for this specific quarter was 2.6%. Looking at the trailing twelve months ending June 28, 2026, the revenue growth year over year was -0.21%. Data from statista.com indicates that revenue for the first quarter of 2026 was reported in billions of U.S. dollars, though the specific value is not provided in the available facts. In terms of profitability, Pfizer reported net income of 7771000000 USD for the year ending December 31, 2025, as stated in its annual SEC filing. For the previous year, ending December 31, 2024, the reported net income was 8031000000 USD. Specific product revenues for 2025 are also documented. NURTEC ODT® / VYDURA® (rimegepant) generated revenue of $1,424 million in 2025. XELJANZ® (tofacitinib) contributed $1,087 million in revenue for the same year. These figures are sourced from annualreview.pfizer.com and reflect the financial performance of these specific products as of 2025. [1] [8] [9] [13]

What the press says

According to 247wallst.com, as of October 30, 2026, Pfizer's dividend yield was reported at 5.82%. The same source also cited a yield of 5.74% in its pharmaceutical sector coverage. For the 2025 period, the company's dividend payout totaled $9.8 billion. This amount represented a payout ratio of 107.7% relative to the company's free cash flow of $9.1 billion for that year. On October 23, 2026, Pfizer's stock price stood at $30.03, according to finance.yahoo.com data dated October 26, 2026. [2] [3] [4]

What the company says

As of 2024, Pfizer states its mission and purpose as "Breakthroughs that change patients’ lives." The company notes that its strategic management options and decisions are based on the requirements of its mission, vision, and purpose. Regarding its vaccine, sources dated November 12, 2020, reported that a preliminary analysis suggested the experimental vaccine was more than 90 percent effective at preventing the disease. These same sources indicated the vaccine was 95 percent effective and appeared to prevent severe disease, with one specific figure citing 94.5 percent effectiveness. Additionally, reports from that date stated the vaccine was 80 percent protective or better. In a source dated December 17, 2021, the text referenced hearing that a vaccine has 95% efficacy and discussed the perception that 90% vaccine efficacy means a specific proportion of vaccinated people will not get the disease. That same 2021 source mentioned that 99.8% of people were involved in a specific context. Another reference from 2020 noted that 94 cases had been confirmed among participants. [10] [11] [12]

Where the sources disagree

  • Firm view is repeated, never independently reported: 90% appears on 2 hosts (www.hartgroup.org, www.scientificamerican.com), none of them a primary source or a data publisher. [10] [11]

Analysis

Pfizer is a long-established New York-based pharmaceutical company that develops prescription medicines and vaccines to serve patients and healthcare systems. [5] [6] [7]

The company reported annual revenue of approximately $62.6 billion for the year ending December 31, 2025, which represents a slight decline from the previous year. [8] [13]

Pfizer generated net income of $7.77 billion in 2025, a decrease from the $8.03 billion reported in 2024. [13]

The company paid out $9.8 billion in dividends in 2025, which exceeded its free cash flow of $9.1 billion, resulting in a payout ratio of 107.7%. [2]

Key products contributing to revenue in 2025 include NURTEC ODT / VYDURA, which generated $1.42 billion, and XELJANZ, which generated $1.09 billion. [1]

Strengths and concerns

Strengths

  • Pfizer generated $62.6 billion in annual revenue for the twelve months ending December 31, 2025, demonstrating its scale as a major pharmaceutical company. [8] [13]
  • The company reported a net income of $7.771 billion for the year ending December 31, 2025, indicating profitability despite revenue fluctuations. [13]
  • Pfizer paid out $9.8 billion in dividends in 2025, reflecting a significant commitment to returning capital to shareholders. [2]
  • The company’s dividend yield stood at 5.82% as of late 2026, offering investors a relatively high income return compared to many peers. [2]
  • Pfizer’s vaccine demonstrated 95% efficacy in preliminary analyses, establishing a strong scientific track record in high-impact therapeutic development. [10]

Concerns

  • Pfizer's annual revenue declined by 1.6% year over year for the twelve months ending December 31, 2025, indicating a contraction in top-line growth. [8]
  • The company's 2025 dividend payout ratio reached 107.7%, meaning it paid out more in dividends than it generated in free cash flow, which signals a strain on cash reserves. [2]
  • Pfizer's net income fell from $8.031 billion in 2024 to $7.771 billion in 2025, representing a decrease in profitability despite maintaining high revenue levels. [13]
  • Revenue growth for the trailing 12 months ending June 28, 2026, was negative at -0.21%, suggesting that the company is currently experiencing a slight revenue decline rather than expansion. [8]

Sources

  1. Pfizer’s year in review | Pfizer 2025 Annual Report
  2. Pfizer: Drug Development and Sourcing – 6 Strategy Analyses 2026–2027 | Pestel-Analysis.co
  3. (PFE) Pfizer Revenue: 1991-2026 Annual Revenue | WallStreetZen

Researched and written by GAR, Octum’s cognitive engine, from the public sources listed above; every figure was checked automatically against the source it cites, and this version was reviewed by Octum before publication. First published 1 November 2026; updated 1 November 2026. Suggest a correction · Read as markdown

More companies research